Aetion is a New York-based platform and service provider for real-world data (RWD) analysis and insights. It was founded in 2013 with the mission to power critical decisions in healthcare with data science-driven technology.
It offers software, partnerships, and expertise for life sciences developers, regulators, and purchasers to generate and substantiate real-world evidence (RWE) for medical innovations.
These solutions are used to analyze real-world data for companies related to the life sciences, payers, regulators, and Health Technology Assessment (HTA) agencies.
Initiatives & Partnerships
Aetion is also involved in various initiatives and partnerships. About half a year ago, the CARE Initiative to identify when and how RWE can improve access and care was launched. CARE facilitates trial emulations, beginning with a focus on oncology. According to the Head of Scientific Strategy of Aetion, Ulka Campbell, “It helps in understanding what can be proxied in real-world data and what cannot, leading to more accurate and relevant findings in oncology studies.”
They also partnered with FDA on advanced analytical techniques and urgent COVID-19 questions.
Products and Services
Aetion offers a range of products and services primarily focused on real-world data (RWD) analysis and insights. These include;
Aetion Evidence Platform® (AEP)
AEP is a RWD management and analytics back-end platform that allows Longitudinal data management across global sources facilitating critical decisions in healthcare.
Aetion® Discover
A fast-start, visual-first descriptive analytics application that helps discern and describe populations and outcomes, treatments, and trends.
Aetion® Substantiate
An advanced analytics application that allows building complex, decision-grade studies without compromising on transparency or reproducibility.
Aetion® Generate
An app and generative artificial intelligence (AI) for synthetic health data generation.
RWE Expertise
Aetion provides data, science, and regulatory services to shape and speed your RWD strategy.
Funding and Valuation
Aetion has secured significant funding to advance its objectives. On May 11, 2021, the company announced a $110 million Series C fundraising round, led by Warburg Pincus, with additional investments from B Capital and Foresite Capital, bringing Aetion’s total funding to $212 million. The funds will be used for the enhancement of Evidence Platform® presence in Europe and the Asia-Pacific region, and to meet increasing demand from biopharma, payer, and medical device/diagnostics clients.
Aetion’s Clientele and Applications
Biopharma Utilization
Aetion’s software and services are being used by biopharmaceutical companies to analyze health data and derive insights for drug development and evaluation.
UCB, a global biopharma company specializing in neurology and immunology, and Evio, a pharmacy solutions provider, use Aetion to assess medication effectiveness, impact, and value.
Payer Engagement
Payers use Aetion’s services to assess healthcare interventions, manage costs, and improve patient outcomes. Other prominent organizations like the Institute for Clinical and Economic Review, work with Aetion to enhance its value assessments of medical treatments.
Regulatory Collaboration
Regulatory agencies, such as the FDA, partner with Aetion to develop frameworks and conduct studies for the evaluation and approval of medical products, including expedited assessments during critical events like the COVID-19 pandemic.
Major Competitors
Some of the competitors of Aetion in the field of RWE include,
TriNetX
A global health research network that optimizes clinical research and enables discoveries through the generation of real-world evidence.
HealthVerity
Offers technology solutions to manage, govern, and explore healthcare data.
Evidera
Provides evidence-based solutions to demonstrate the real-world effectiveness, safety, and value of healthcare products.